Newron Pharmaceuticals (NWRNZ) Stock Overview

A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. More details

NWRNZ fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	6/6
Past Performance	3/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 88.7% below our estimate of its fair value

Earnings are forecast to grow 45.19% per year

Became profitable this year

Risk Analysis

Shares are highly illiquid

Has a high level of debt

NWRNZ Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Newron Pharmaceuticals S.p.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Newron Pharmaceuticals
Historical stock prices
Current Share Price	CHF 15.78
52 Week High	CHF 16.02
52 Week Low	CHF 13.20
Beta	0.68
1 Month Change	19.00%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	35.57%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	NWRNZ	GB Pharmaceuticals	GB Market
7D	9.9%	-0.3%	-3.4%
1Y	n/a	29.6%	16.4%

Return vs Industry: Insufficient data to determine how NWRNZ performed against the UK Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how NWRNZ performed against the UK Market.

Price Volatility

Is NWRNZ's price volatile compared to industry and market?
NWRNZ volatility
NWRNZ Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.6%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: NWRNZ's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine NWRNZ's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	22	Stefan Weber	www.newron.com

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication.

Newron Pharmaceuticals S.p.A. Fundamentals Summary

How do Newron Pharmaceuticals's earnings and revenue compare to its market cap?
NWRNZ fundamental statistics
Market cap	CHF 315.38m
Earnings (TTM)	CHF 23.45m
Revenue (TTM)	CHF 55.43m

13.5x

P/E Ratio

5.7x

P/S Ratio

Is NWRNZ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NWRNZ income statement (TTM)
Revenue	€59.88m
Cost of Revenue	€0
Gross Profit	€59.88m
Other Expenses	€34.55m
Earnings	€25.33m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	1.27
Gross Margin	100.00%
Net Profit Margin	42.30%
Debt/Equity Ratio	3,276.4%

How did NWRNZ perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/18 17:56
End of Day Share Price	2025/11/18 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Newron Pharmaceuticals S.p.A. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Thomas Meyer	Baader Helvea Equity Research
Jyoti Prakash	Edison Investment Research
Lucy Codrington	Jefferies LLC